Start Date
May 31, 2019
Primary Completion Date
May 31, 2022
Study Completion Date
May 31, 2022
Dabigatran
At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up.
Placebo - Cap
At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up
Collaborators (1)
Alzheimer's Drug Discovery Foundation
OTHER
Boehringer Ingelheim
INDUSTRY
University of Rhode Island
OTHER